A Phase II Open-Label Study of Ganetespib, a Novel Heat Shock Protein 90 Inhibitor for Patients With Metastatic Breast Cancer

• Published in: Clinical breast cancer Vol. 14; no. 3; pp. 154 - 160
• Main Authors: Jhaveri, Komal, Chandarlapaty, Sarat, Lake, Diana, Gilewski, Teresa, Robson, Mark, Goldfarb, Shari, Drullinsky, Pamela, Sugarman, Steven, Wasserheit-Leiblich, Carolyn, Fasano, Julie, Moynahan, Mary Ellen, D'Andrea, Gabriella, Lim, Kristina, Reddington, Laura, Haque, Sofia, Patil, Sujata, Bauman, Lynne, Vukovic, Vojo, El-Hariry, Iman, Hudis, Clifford, Modi, Shanu
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2014
• Subjects: Adult; Aged; Antineoplastic Agents - therapeutic use; Breast cancer; Breast Neoplasms - drug therapy; Breast Neoplasms - mortality; Disease-Free Survival; Female; Ganetespib; Hematology, Oncology and Palliative Medicine; HER2; HSP90; HSP90 Heat-Shock Proteins - antagonists & inhibitors; Humans; Kaplan-Meier Estimate; Middle Aged; Monotherapy; Neoplasm Metastasis; Obstetrics and Gynecology; Triazoles - therapeutic use; HSP90; Ganetespib; Breast cancer; HER2; Monotherapy
• ISSN: 1526-8209; 1938-0666
• DOI: 10.1016/j.clbc.2013.12.012

Micro-Abstract This phase II trial evaluated the role of single agent ganetespib, an Heat Shock Protein 90 (HSP90) inhibitor, in unselected Metastatic Breast Cancer (MBC). The study did not meet its prespecified criteria for overall response rate (ORR) in this heavily pretreated population. However, clinical activity was noted in HER2-positive and triple-negative breast cancer (TNBC), which warrants further study as part of rational combinations.